[SGLT2i:探索心血管保护的多种途径. [关于营养缺乏的洞察]
Fabio Mazza1, Francesca Apponi2, Angela Cicciarelli1
1UO Nefrologia e Dialisi, Ospedale SS Trinità Sora, Italia.
概括
-葡萄糖共运输体2 (SGLT-2) 抑制剂通过改变营养剥夺途径来模仿卡路里限制. 这种机制有助于这些抗糖尿病药物所观察到的独特心脏脏益处.
科学领域:
- 内分泌学 在内分泌学.
- 代谢途径 代谢途径
- 药理学 药理学是指药理学的学科.
背景情况:
- -葡萄糖共运输体2 (SGLT-2) 抑制剂代表了一种新的抗糖尿病药物类别.
- 这些药物调节细胞信号通路.
- 它们独特的治疗特性超出了血糖控制的范围.
研究的目的:
- 为了阐明受SGLT-2抑制剂影响的营养缺乏途径.
- 为了将这些通路与观察到的心脏脏保护作用联系起来.
- 突出SGLT-2抑制剂明显益处的机制基础.
主要方法:
- 对SGLT-2抑制剂和细胞代谢现有文献的综述.
- 分析与营养缺乏相关的转录反应.
- 对SIRT1,AMPK和mTOR等信号分子的检查.
主要成果:
- SGLT-2 抑制剂诱导了一种类似于卡路里限制的转录特征.
- 关键的营养剥夺传感器 (SIRT1,AMPK) 进行了上调.
- 与营养过剩 (mTOR) 相关的信号通路被下调.
结论:
- SGLT-2 抑制剂的心性益处部分通过激活营养剥夺途径来调解.
- 这种复杂的机制框架将SGLT-2抑制剂与其他抗糖尿病药物区分开来.
- 了解这些途径为新的治疗策略提供了见解.
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
943
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
943
Acute Kidney Injury II: Pathophysiology
910
Acute kidney injury (AKI) causes are categorized into three primary categories based on the location of the injury: prerenal, intrarenal (or intrinsic), and postrenal causes. This classification guides clinical management and illustrates how different pathways can impair kidney function.Etiology and Pathophysiology of Acute Kidney Injury1. Prerenal causesEtiology: Prerenal Acute Kidney Injury, the most common type, occurs when reduced blood flow to the kidneys decreases filtration capacity...
910
Antihypertensive Drugs: Direct Renin Inhibitors
1.3K
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.3K
Heart Failure Drugs: Diuretics
812
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
812
Heart Failure V: Medical Management
223
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
223
Acute Kidney Injury IV: Diagnostic Studies and Prevention
271
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
271


